Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
conventional treatment-Nazarbayev University
- Development stage
- Unknown
- Lead developer
- Nazarbayev University
- Modality
- Small Molecules, Peptides
- Administration
- Oral, Subcutaneous
01
Overview
The 'conventional treatment-Nazarbayev University' refers to the standardized pharmacological regimen used as the control arm in the PCSAM (Comparative Physical and Chemical Study of the Mechanisms of Atherosclerosis) clinical trial (NCT02543840). This multi-drug protocol was designed by researchers at Nazarbayev University to manage patients with atherosclerosis and associated metabolic comorbidities, including hypertension, dyslipidemia, and type 2 diabetes. The regimen includes atorvastatin (Liprimar) for lipid lowering, lisinopril (Diroton) and diltiazem for blood pressure control, metformin or exenatide for glycemic management, and aspirin (TromboACC) or clopidogrel for antiplatelet therapy. The trial compared this conventional pharmacological approach to a lifestyle-based intervention consisting of a very low-calorie vegetable diet and increased physical activity.
- Other names
- Conventional pharmacological treatmentPCSAM conventional treatment
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AMPK (Adenosine monophosphate–activated protein kinase)ACE (Angiotensin Converting Enzyme)PGHS-1 (Prostaglandin G/H Synthase 1)GLP1R (GLP-1R)LTCC (Voltage-gated calcium channel (L-type))P2Y12 (Purinergic P2Y12 receptor)
Beyond the preview
Go deeper on conventional treatment-Nazarbayev University.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on conventional treatment-Nazarbayev University.